These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28449227)

  • 1. Apremilast for a psoriasis patient with HIV and hepatitis C.
    Reddy SP; Shah VV; Wu JJ
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e481-e482. PubMed ID: 28449227
    [No Abstract]   [Full Text] [Related]  

  • 2. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
    Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
    Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
    [No Abstract]   [Full Text] [Related]  

  • 3. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus.
    Reddy SP; Lee E; Wu JJ
    Cutis; 2019 May; 103(5):E6-E7. PubMed ID: 31233584
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast.
    Waki Y; Kamiya K; Komine M; Maekawa T; Murata S; Ishii N; Hashimoto T; Ohtsuki M
    Eur J Dermatol; 2018 Jun; 28(3):413-414. PubMed ID: 29619999
    [No Abstract]   [Full Text] [Related]  

  • 5. Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
    Vico-Alonso C; Sánchez-Velázquez A; Pinilla-Martin B; Andrés-Lencina JJ; Aragón-Miguel R; Calleja-Algarra A; Rivera-Díaz R
    Int J Dermatol; 2020 Apr; 59(4):e102-e103. PubMed ID: 31347142
    [No Abstract]   [Full Text] [Related]  

  • 6. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
    Manfreda V; Esposito M; Campione E; Bianchi L; Giunta A
    Postgrad Med; 2019 Apr; 131(3):239-240. PubMed ID: 30700196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast, beyond psoriasis as a therapeutic target.
    Ruiz-Villaverde R; Bueno-Rodriguez A; Tercedor-Sánchez J
    Med Clin (Barc); 2017 Jul; 149(1):42-43. PubMed ID: 28242122
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment.
    Muñoz-Santos C; Sola-Ortigosa J; Guilabert A
    Clin Exp Dermatol; 2018 Jul; 43(5):606-607. PubMed ID: 29453771
    [No Abstract]   [Full Text] [Related]  

  • 9. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.
    Peitsch WK
    J Dtsch Dermatol Ges; 2019 Mar; 17(3):330-332. PubMed ID: 30775841
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
    Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
    J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.
    Fattore D; Annunziata MC; Panariello L; Marasca C; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():107-109. PubMed ID: 30785013
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
    Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
    Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Ortiz-Salvador JM; Subiabre-Ferrer D; Hernández-Bel P
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of psoriasis vulgaris with apremilast in a patient with decompensated cirrhosis.
    Yatsuzuka K; Murakami M; Yoshida S; Utsunomiya R; Watanabe T; Sayama K
    J Dermatol; 2022 Apr; 49(4):e129-e130. PubMed ID: 34854129
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis.
    Garbayo Salmons P; Expósito Serrano V; Romaní de Gabriel J; Ribera Pibernat M
    Actas Dermosifiliogr; 2022 May; 113(5):532-535. PubMed ID: 35697416
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Walsh S; Shear NH; Yeung J
    J Am Acad Dermatol; 2018 Mar; 78(3):623-626. PubMed ID: 28989112
    [No Abstract]   [Full Text] [Related]  

  • 18. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
    Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
    Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.
    Sacchelli L; Patrizi A; Loi C; Bardazzi F
    Clin Exp Dermatol; 2019 Oct; 44(7):e243-e244. PubMed ID: 31055844
    [No Abstract]   [Full Text] [Related]  

  • 20. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.